RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event.

Conference Details:

Event: 15th Annual Craig-Hallum Alpha Select Conference
Date: November 19, 2024
Location: Sheraton New York Times Square Hotel, New York City

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.

For further information, please contact:

Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate & Media:
Lindsay Rocco 
Elixir Health Public Relations
+1 862-596-1304
This email address is being protected from spambots. You need JavaScript enabled to view it.